Recent Pfizer Press Releases

  • 11/18/15 7:00 am EST
    • Breakthrough Therapy designation highlights the potential of avelumab* as a new immunotherapy for patients with metastatic Merkel cell carcinoma (MCC)
    • Metastatic MCC is a devastating disease and if approved, avelumab could potentially become the first immunotherapy to treat metastatic MCC
    DARMSTADT, Germany & NEW YORK--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, and Pfizer today announced that the US Food and Drug Administration (FDA) has granted avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designation for the treatment of patients with metastatic Merkel cell carcinoma (MCC) who have progressed after at least one previous chemotherapy regimen. Breakthrough Therapy designation is designed to accelerate the developmentmore...
  • 11/16/15 4:00 am EST

    - Trachoma is the Leading Infectious Cause of Blindness -

    - More Than 100 Government, Non-Governmental and Private Sector Partners Driving Progress -

    - Continued Efforts Needed to Reach 2020 Global Elimination Goal -

    NEW YORK--(BUSINESS WIRE)--The International Trachoma Initiative (ITI), Pfizer Inc. and International Coalition for Trachoma Control (ICTC) partners announce Pfizer’s donation of the 500 millionth dose of Zithromax® (azithromycin) Tablets, an antibiotic used to treat trachoma in certain countries. The milestone marks significant achievement in global efforts to help eliminate this infectious and preventable eye disease that can lead to permanent blindness asmore...
  • 11/6/15 4:15 pm EST

    Twenty-two Abstracts to be Presented, Including New Data Analyses from the ARISTOTLE Pivotal Phase 3 Study and Real-World Data Analyses

    PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (PFE) announced today that 22 abstracts will be presented at the American Heart Association (AHA) Scientific Sessions 2015, to be held November 7-11 in Orlando, Florida. The new data, including four oral presentations, contribute to the Bristol-Myers Squibb and Pfizer Alliance’s research in nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE) in patients treatedmore...
  • 11/5/15 8:00 am EST

    Program Offers Assistance to Insured and Uninsured Patients

    NEW YORK--(BUSINESS WIRE)--In response to the ongoing challenges patients face in paying their out-of-pocket costs for their prescription medicines, Pfizer announced today that it will immediately double the allowable income level for its patient assistance program, so that even more patients in need could be eligible to receive their Pfizer medicines for free. With this change, more than 40 medicines offered for free through the program will now be available to eligiblemore...
  • 11/5/15 7:00 am EST

    First-of-its-kind Global Report Commissioned by Pfizer, Working Collaboratively with the European School of Oncology, Aims to Catalyze a Global Call-to-Action to Improve Metastatic Breast Cancer Outcomes by 2025

    Preliminary Findings to be Presented at the Advanced Breast Cancer Third International Consensus Conference (ABC3)

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc., working collaboratively with the European School of Oncology (ESO), within the scope of the Advanced Breast Cancer Third International Consensus Conference (ABC3), today released the Global Status of Metastatic Breast Cancer (MBC): A 2005 – 2015 Decade Report, which revealed both areas of improvement and substantial gaps in care, access to resources and support, and treatment outcomes for women with MBC. MBC is themore...
  • 11/4/15 8:00 am EST
    • Trial marks second Phase III study of avelumab in non-small cell lung cancer (NSCLC) initiated by Merck and Pfizer in just over six months
    • Primary endpoint is progression-free survival in previously untreated patients with recurrent or Stage IV programmed death-ligand 1 positive (PD-L1+) NSCLC
    DARMSTADT, Germany & NEW YORK--(BUSINESS WIRE)--Not intended for UK-based media Merck and Pfizer today announced the initiation of an international Phase III study of the investigational cancer immunotherapy avelumab* in a treatment naïve advanced NSCLC setting. The study, JAVELIN Lung 100, is designed to assess the safety and efficacy of avelumab compared with platinum-based doublet chemotherapy, in patients with late-stage NSCLC who have not previously received any treatment formore...
  • 11/4/15 8:00 am EST
    • Trial marks second Phase III study of avelumab in non-small cell lung cancer (NSCLC) initiated by Merck KGaA, Darmstadt, Germany, and Pfizer in just over six months
    • Primary endpoint is progression-free survival in previously untreated patients with recurrent or Stage IV programmed death-ligand 1 positive (PD-L1+) NSCLC
    DARMSTADT, Germany & NEW YORK--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, and Pfizer today announced the initiation of an international Phase III study of the investigational cancer immunotherapy avelumab* in a treatment naïve advanced NSCLC setting. The study, JAVELIN Lung 100, is designed to assess the safety and efficacy of avelumab compared with platinum-based doublet chemotherapy, in patients with late-stage NSCLC who have not previously received any treatment for their systemicmore...
  • 11/2/15 8:06 am EST

    Twenty-six Pfizer scientific abstracts will be presented for the first time at the ACR/ARHP 2015 Annual Meeting

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that 26 new scientific abstracts, including 20 presentations for XELJANZ® (tofacitinib citrate) in rheumatoid arthritis (RA) will be presented on behalf of Pfizer at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) 2015 Annual Meeting (November 7-11, San Francisco, CA). “Ongoing clinical trials and long term extension studies provide importantmore...
  • 10/30/15 10:27 pm EDT
    NEW YORK--(BUSINESS WIRE)--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013, Pfizer Inc. (NYSE:PFE) (the "Company") confirms that, at the close of business on October 29, 2015, its issued share capital, excludingmore...
  • 10/29/15 10:09 am EDT
    NEW YORK--(BUSINESS WIRE)--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Pfizer notes the announcement by Allergan that was released earlier today regarding a potential transaction between the companies. Pfizer confirms that it is in preliminary friendly discussions with Allergan in relation to a potential transactionmore...